Fewer Major Bleeds With Once- Versus Twice-Daily Enoxaparin

Share this content:
Fewer Major Bleeds With Once- Versus Twice-Daily Enoxaparin
Fewer Major Bleeds With Once- Versus Twice-Daily Enoxaparin

MONDAY, Feb. 6, 2017 (HealthDay News) -- Once-daily enoxaparin is associated with fewer major bleeds than enoxaparin twice daily in patients with acute venous thromboembolism (VTE), according to a study published online Jan. 25 in the Journal of Thrombosis and Haemostasis.

Javier Trujillo-Santos, M.D., Ph.D., from the Hospital General Universitario Santa Lucía in Murcia, Spain, and colleagues assessed data from the RIETE registry for 4,730 patients receiving enoxaparin: 3,786 and 944 received enoxaparin twice and once daily, respectively.

The researchers found that, compared with those receiving enoxaparin twice daily, once-daily enoxaparin correlated with a trend toward more VTE recurrences (odds ratio [OR], 1.79; 95 percent confidence interval [CI], 0.55 to 5.88), fewer major bleeds (OR, 0.42; 95 percent CI, 0.17 to 1.08), and fewer deaths (OR, 0.32; 95 percent CI, 0.13 to 0.78) during the first 15 days. Patients on enoxaparin once daily had more VTE recurrences (OR, 2.5; 95 percent CI, 1.03 to 5.88), fewer major bleeds (OR, 0.40; 95 percent CI, 0.17 to 0.94), and fewer deaths (OR, 0.58; 95 percent CI, 0.33 to 1.00) at day 30. On propensity analysis, patients on enoxaparin once daily had fewer bleeds at 15 and 30 days (hazard ratios, 0.30 [95 percent CI, 0.10 to 0.88] and 0.16 [95 percent CI, 0.04 to 0.68]) and fewer deaths at 15 and 30 days (hazard ratios, 0.37 [95 percent CI, 0.14 to 0.99] and 0.19 [95 percent CI, 0.07 to 0.54]).

"Enoxaparin prescribed once daily results in fewer major bleeds than enoxaparin twice daily," the authors write.

The RIETE registry was supported by Sanofi Spain and Bayer Pharma AG.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves New Parkinson's Add-On Drug Xadago

FDA Approves New Parkinson's Add-On Drug Xadago

To help prevent 'off' episodes among users of levodopa/carbidopa

Infant Mortality Down in United States From 2005 to 2014

Infant Mortality Down in United States From 2005 ...

Largest decreases seen for infants of Asian or Pacific Islander and non-Hispanic black women

Intensive Strategy Addresses Hypoxemia After Cardiac Surgery

Intensive Strategy Addresses Hypoxemia After Cardiac Surgery

Intensive alveolar recruitment strategy linked to less severe pulmonary complications after cardiac sx

is free, fast, and customized just for you!

Already a member?

Sign In Now »